Drug archive
Daclizumab (Systemic)
Archived drug information. This USP DI monograph is kept for reference and dates from the mid-2000s. Doses, warnings, interactions and brand names may have changed, and some products are no longer sold. Always follow your prescriber, your pharmacist and the current label, for example on DailyMed.
Category
- Immunosuppressant
- monoclonal antibody
Description
Daclizumab (da-KLIZ-yoo-mab) belongs to a group of medicines known as immunosuppressive agents. It is used to lower the body's natural immunity in patients who receive kidney transplants.
When a patient receives a kidney transplant, the body's white blood cells will try to get rid of (reject) the transplanted kidney. Daclizumab works by preventing the white blood cells from getting rid of the transplanted kidney. The effect of daclizumab on the white blood cells may also reduce the body's ability to fight infections.
Daclizumab is to be administered only by or under the immediate supervision of your doctor. It is available in the following dosage form:
- Injection (U.S.)
Brand Names
Some commonly used brand names are:
In the U.S. -
- Zenapax
Another commonly used name is dacliximab .